SEARCH

SEARCH BY CITATION

References

  • 1
    Mom T, Avan P, Gilian L. Les surdités brusques idiopathiques. Rev Méd Interne 2002; 23: 292307.
  • 2
    Mattox DE, Lyles CA. Idiopathic sudden sensorineural hearing loss. Am J Otol 1989; 10: 2427.
  • 3
    Lalanne MC, Doutremepuich C, Boj F, Traissac L, Quichaud F. Some hemostatic and hemorheological disorders in auditory and vestibular impairments. Thromb Res 1992; 66: 78791.
  • 4
    Einer H, Tengborn L, Axelsson A, Edstrom S. Sudden sensorineural hearing loss and hemostatic mechanisms. Arch Otolaryngol Head Neck Surg 1994; 120: 53640.
  • 5
    Scheibe F, Haupt H, Baumgartl H. Effects of experimental cochlear thrombosis on oxygenation and auditory function of the inner ear. Eur Arch Otorhinolaryngol 1997; 254: 914.
  • 6
    Schwitter J, Agosti R, Ott P, Kalman A, Waespe W. Small infarctions of cochlear, retinal, and encephalic tissue in young women. Stroke 1992; 23: 9037.
  • 7
    Browning GG, Gatehouse S, Lowe GDO. Blood viscosity as a factor in sensorineural hearing impairment. Lancet 1986; 1: 1213.
  • 8
    Ohinata Y, Makimoto K, Kawakami M, Haginomori S, Araki M, Takahashi H. Blood viscosity and plasma viscosity in patients with sudden deafness. Acta Otolaryngol 1994; 114: 6017.
  • 9
    Patscheke JH, Arndt J, Dietz K, Zenner HP, Reuner KH. The prothrombin G20210A mutation is a risk factor for sudden hearing loss in young patients. Thromb Haemost 2001; 86: 11189.
  • 10
    Gold S, Kamerer DB, Hirsch BE, Cass SP. Hypercoagulability in otologic patients. Am J Otolaryngol 1993; 14: 32731.
  • 11
    Mercier E, Quere I, Chabert R, Lallemant JG, Daures JP, Berlan J, Gris JP. The 20210A allele of the prothrombin gene is an independent risk factor for perception deafness in patients with venous thromboembolic antecedents. Blood 1999; 93: 31502.
  • 12
    Chobainian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JRJL, Jones DW, Materson BJ, Oparil S, Wright JJT, Roccella JT. The seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289: 256071.
  • 13
    Anonymous. Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adult (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143421.
  • 14
    Anonymous. Reports of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003; 26: S520.
  • 15
    Cadoni G, Agostino S, Scipione S, Galli J. Low serum folate levels: a risk factor for sudden sensorineural hearing loss? Acta Otolaryngol 2004; 124: 60811.
  • 16
    Toubi E, Ben-David J, Kessel A, Podoshin L, Golan TD. Autoimmune aberration in sudden sensorineural hearing loss: association with anti-cardiolipin antibodies. Lupus 1997; 6: 5402.
  • 17
    Wang MS, Wang XX, Chen XD, Chen JF. Study on the coagulation state of sudden deafness. Lin Chuang Er Bi Yan Hou Ke Za Zhi 2000; 14: 3057.
  • 18
    Gensini GF, Comeglio M, Colella A. Classical risk factors and emerging elements in the risk profile for coronary artery disease. Eur Heart J 1998; 19 (Suppl. A): A5361.
  • 19
    Leys D, Deplanque D, Mounier-Vehier C, Mackowiak-Cordoliani MA, Lucas C, Bordet R. Stroke prevention: management of modifiable vascular risk factors. J Neurol 2002; 249: 50717.
  • 20
    Kim CK, Schmalfuss CM, Schofield RS, Sheps DS. Pharmacological treatment of patients with peripheral arterial disease. Drugs 2003; 63: 63747.
  • 21
    Satar B, Ozkaptan Y, Surucu HS, Ozturk H. Ultrastructural effects of hypercholesterolemia on the cochlea. Otol Neurotol 2001; 22: 7869.
  • 22
    Suzuki K, Kaneko M, Murai K. Influence of serum lipids on auditory function. Laryngoscope 2000; 110: 17368.
  • 23
    Cattaneo M. Hyperhomocysteinemia and atherothrombosis. Ann Med 2000; 32: 4652.
  • 24
    Schwammenthal Y, Tanne D. Homocysteine, B-vitamin supplementation, and stroke prevention: from observational to interventional trials. Lancet Neurol 2004; 3: 4935.
  • 25
    Darius H, Pittrow D, Habert R, Trampisch HJ, Schuster A, Lange S, Tepohl HG, Allenberg JL, Diehm C. Are elevated homocysteine plasma levels related to peripheral arterial disease? Results from a cross-sectional study of 6880 primary care patients. Eur J Clin Invest 2003; 33: 7517.
  • 26
    Schnyder G, Roffi M, Flammer Y, Lange H, Eberli FR, Meier B, Turi ZG, Hess OM. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001; 345: 1593600.
  • 27
    Lange H, Suryapranata H, De Luca G, Borner C, Dille J, Kallmayer K, Pasalary MN, Scherer E, Dambrink JH. Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med 2004; 350: 267381.
  • 28
    Marcucci R, Zanazi M, Bertoni E, Rosati A, Fedi S, Lenti M, Prisco D, Castellani S, Abbate R, Salvadori M. Vitamin supplementation reduces the progression of atherosclerosis in hyperhomocysteinemic renal-transplant recipients. Transplantation 2003; 75: 15515.
  • 29
    Abbate R, Sardi I, Pepe G, Marcucci R, Brunelli T, Prisco D, Fatini C, Capanni M, Simonetti I, Gensini GF. The high prevalence of thermolabile 5–10 methylenetetrahydrofolate reductasa (MTHFR) in Italians is not associated to an increased risk for coronary artery disease (CAD). Thromb Haemost 1998; 79: 72730.
  • 30
    Selhub J. Homocysteine metabolism. Annu Rev Nutr 1999; 19: 21746.
  • 31
    Selhub J. Folate, vitamin B12 and vitamin B6 and one carbon metabolism. J Nutr Health Aging 2002; 6: 3942.
  • 32
    Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000; 342: 1792801.
  • 33
    Lijnen HR. Pleiotropic functions of plasminogen activator inhibitor-1. J Thromb Haemost 2005; 3: 3545.
  • 34
    Kaba NK, Francis CW, Moss AJ, Zareba W, Oakes D, Knox KL, Fernandez ID, Rainwater DL, THROMBO Investigators. Effects of lipids and lipid-lowering therapy on hemostatic factors in patients with myocardial infarction. J Thromb Haemost 2004; 2: 71825.
  • 35
    Krysiak R, Okopien B, Herman Z. Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Drugs 2003; 63: 182154.
  • 36
    Green L, Miller EB. Sudden sensorineural hearing loss as a first manifestation of systemic lupus erythematosus: association with anticardiolipin antibodies. Clin Rheumatol 2001; 20: 2202.
  • 37
    Toubi E, Ben-David J, Kessel A, Halas K, Sabo E, Luntz M. Immune-mediated disorders associated with idiopathic sudden sensorineural hearing loss. Ann Otol Rhimol Laryngol 2004; 113: 4549.
  • 38
    Chapman J, Rand JH, Brey RL, Levine SR, Blatt I, Khamashta MA, Shoenfeld Y. Non-stroke neurological syndromes associated with antiphospholipid antibodies: evaluation of clinical and experimental studies. Lupus 2003; 12: 5147.
  • 39
    Naarendorp M, Spiera H. Sudden sensorineural hearing loss in patients with systemic lupus erythematosus or lupus-like syndromes and antiphospholipid antibodies. J Rheumatol 1998; 25: 58992.